NIB
Non-imaging Biomarkers
Thursday, June 2, 2022: 5:00 PM-7:00 PM
Prince George's Exhibit Hall (Gaylord National Resort & Convention Center)
Nurown (MSC-NTF) Phase 2 Clinical Trial in Progressive MS: Effects on CSF Inflammatory Biomarkers
Christopher B. Lock, MD, PhD, Stanford School of Medicine;
Jeffrey A Cohen, MD, Mellen MS Center, Cleveland Clinic;
Fred D. Lublin, MD, Corinne Goldsmith Dickinson Center for Multiple Sclerosis;
Daniel Pelletier, MD, Keck School of Medicine of University of Southern California;
Tanuja Chitnis, MD, Harvard Medical School;
Munish Mehra, PhD, Tigermed;
Yael Gothelf, Ph.D., Brainstorm Cell Therapeutics;
Revital Aricha, PhD, Brainstorm Cell Therapeutics;
Stacy Lindborg, PhD, Brainstorm Cell Therapeutics;
Chaim Lebovits, CEO, Brainstorm Cell Therapeutics;
Ralph Kern, MD, MHSc, Brainstorm Cell Therapeutics
Multivariate Proteomic MS Disease Activity Test Results Surfaces Both Individual Patient and Clinical Practice Population Insights
Ferhan Qureshi, BS, Octave Bioscience, Inc.;
Tammy Hoyt, MS, Rocky Mountain Multiple Sclerosis Clinic;
Angel Christensen, BS, Rocky Mountain Multiple Sclerosis Clinic;
Fatima Rubio da Costa, PhD, Octave Bioscience, Inc.;
Victor Gehman, PhD, Octave Bioscience, Inc.;
Fujun Zhang, MS, Octave Bioscience, Inc.;
David Hughes, BSN, Octave Bioscience, Inc.;
John Foley, MD, Rocky Mountain MS Clinic
Prodromal Symptoms and Health Care Utilization in Pediatric Onset Multiple Sclerosis Prior to Diagnosis
Rachel Zolno, MD, Washington University in St. Louis;
Natalie Schanzer, BA, Washington University in St. Louis;
Kayleigh Lewis, N/A, Washington University in St. Louis;
Connor Keuchel, BA, Washington University in St. Louis;
Siefaddeen Sharayah, MD, Washington University in St. Louis;
Cristina Gaudioso, MD, Washington University in St. Louis;
Soe Mar, MD, Washington University in St. Louis
